Shriya Dhingra (@shriyadhingra_) 's Twitter Profile
Shriya Dhingra

@shriyadhingra_

Science and Conscience. Antsy and Artsy. Living for accidental discoveries.

ID: 1563738214342574081

calendar_today28-08-2022 04:00:27

79 Tweet

79 Followers

235 Following

Nat Lester-Coll, MD (@drlestercoll) 's Twitter Profile Photo

Decommissioning a linac means we get to make electron trees! ⚑️🌲 These 3D β€˜lightning bolt’ patterns are created when high-voltage electrons branch through acrylic, leaving behind a permanent fractal design #radonc

Decommissioning a linac means we get to make electron trees! ⚑️🌲 

These 3D β€˜lightning bolt’ patterns are created when high-voltage electrons branch through acrylic, leaving behind a permanent fractal design

#radonc
Dr. Nina Niu Sanford (@niusanford) 's Twitter Profile Photo

RACE-GB is out! Congrats to authors for FIRST RCT of RT in gallbladder cancer. N=135 w unresectable GBC, after 4c chemo, addition of RT (vs. obs) improved OS from 4 to 10 months. Several limitations (single center, chemo gem/cis & 4 mo) but OS benefit shouldn’t be ignored.

RACE-GB is out! Congrats to authors for FIRST RCT of RT in gallbladder cancer.

N=135 w unresectable GBC, after 4c chemo, addition of RT (vs. obs) improved OS from 4 to 10 months.

Several limitations (single center, chemo gem/cis & 4 mo) but OS benefit shouldn’t be ignored.
Drew Moghanaki (@drewmoghanaki) 's Twitter Profile Photo

It took this entire wall of books to print out the human genome. Zoom in to see the nucleotide sequences. Pic taken at @EllisonInst

It took this entire wall of books to print out the human genome. Zoom in to see the nucleotide sequences. 

Pic taken at @EllisonInst
Pashtoon Kasi MD, MS (@pashtoonkasi) 's Twitter Profile Photo

πŸ’‘All about efficiency. Subcutaneous nivolumab nowβœ…FDA approved across indications. Especially for combination regimens and long infusion/chair times, this route is appealing given how commonly these PD1⛔️immunotherapies are used in clinic. OncoAlert fda.gov/drugs/resource…

πŸ’‘All about efficiency. Subcutaneous nivolumab nowβœ…FDA approved across indications. Especially for combination regimens and long infusion/chair times, this route is appealing given how commonly these PD1⛔️immunotherapies are used in clinic.

<a href="/OncoAlert/">OncoAlert</a>

fda.gov/drugs/resource…
Tata Memorial Hospital (@tatamemorial) 's Twitter Profile Photo

The 2001 The Nobel Prize laureate Prof. Sir Paul Nurse for his groundbreaking work on the cell cycle, will deliver a talk on β€˜Controlling the Cell Cycle’ on 29.5 at 2.30 pm Tata Memorial Hospital. You can catch it live streamed on our YT channel as well! DAE IndiaΒ  youtube.com/@TataMemorialC…

The 2001 <a href="/NobelPrize/">The Nobel Prize</a> laureate Prof. Sir Paul Nurse for his groundbreaking work on the cell cycle, will deliver a talk on β€˜Controlling the Cell Cycle’ on 29.5 at 2.30 pm <a href="/TataMemorial/">Tata Memorial Hospital</a>. You can catch it live streamed on our YT channel as well! <a href="/DAEIndia/">DAE India</a>Β 
youtube.com/@TataMemorialC…
Stephen V Liu, MD (@stephenvliu) 's Twitter Profile Photo

This is a major story from #ASCO25. Randomized phase 3 trial of time of day of immunotherapy infusion. Randomized to infusion before or after 3pm. Early infusion far superior: PFS 11.3 vs 5.7 HR 0.42, OS HR 0.45! Impactful, pragmatic, not costly. This should be a bigger story.

This is a major story from #ASCO25. Randomized phase 3 trial of time of day of immunotherapy infusion. Randomized to infusion before or after 3pm. Early infusion far superior: PFS 11.3 vs 5.7 HR 0.42, OS HR 0.45! Impactful, pragmatic, not costly. This should be a bigger story.
TMC Radiation Oncology (@radonctmc) 's Twitter Profile Photo

πŸŽ‰ Congratulations to Shriya Dhingra on receiving the HBNI Outstanding Student Award 2024! We’re sure you’ll continue to do well and make a difference for years to come! πŸ‘

πŸŽ‰ Congratulations to <a href="/ShriyaDhingra_/">Shriya Dhingra</a> on receiving the HBNI Outstanding Student Award 2024!

We’re sure you’ll continue to do well and make a difference for years to come! πŸ‘
Anirban Maitra (@aiims1742) 's Twitter Profile Photo

Absolutely insane amount of data in this resource from Chris Mason The Spatial Atlas of Human Anatomy (SAHA): A Multimodal Subcellular-Resolution Reference Across Human Organs biorxiv.org/content/10.110… Spatial data on 15million cells from 100 donors across multiple ages, mainly GI

Absolutely insane amount of data in this resource from <a href="/mason_lab/">Chris Mason</a> 
The Spatial Atlas of Human Anatomy (SAHA): A Multimodal Subcellular-Resolution Reference Across Human Organs 
biorxiv.org/content/10.110…
Spatial data on 15million cells from 100 donors across multiple ages, mainly GI
Rahul Banerjee, MD, FACP (@rahulbanerjeemd) 's Twitter Profile Photo

πŸ‘ I saw an interesting anecdote and just looked up the reference. Literally before I was born, an oncologist very succinctly and elegantly summarized how we offer hope to our patients living with cancer... these words are still true today! pubmed.ncbi.nlm.nih.gov/18750361/

πŸ‘ I saw an interesting anecdote and just looked up the reference.

Literally before I was born, an oncologist very succinctly and elegantly summarized how we offer hope to our patients living with cancer... these words are still true today!

pubmed.ncbi.nlm.nih.gov/18750361/
Allen Institute (@alleninstitute) 's Twitter Profile Photo

Forget how your biology textbooks depicted the endoplasmic reticulum. @hhmijanelia scientist Andrew Moore used our open graphics tool AGAVE to create this image showing the ER's outer membrane. The tool borrows animation studio techniques to create realistic light sources.

Forget how your biology textbooks depicted the endoplasmic reticulum.

@hhmijanelia scientist Andrew Moore used our open graphics tool AGAVE to create this image showing the ER's outer membrane. The tool borrows animation studio techniques to create realistic light sources.
JAMA Oncology (@jamaonc) 's Twitter Profile Photo

Viewpoint discusses how oncology drug development is shifting from immunotherapy to targeted therapies like antibody-drug conjugates and radioligand therapy. ja.ma/3GSEPOQ

Viewpoint discusses how oncology drug development is shifting from immunotherapy to targeted therapies like antibody-drug conjugates and radioligand therapy. 

ja.ma/3GSEPOQ
Drew Moghanaki (@drewmoghanaki) 's Twitter Profile Photo

New data from the randomized PEMBRO-RT study demonstrate when an ICI-mediated Abscopal effect is most likely to occur in patients with stage IV NSCLC. Ralph Weichselbaum Sean Pitroda, M.D. Amy L. Cummings, MD PhD doi.org/10.1038/s43018…

New data from the randomized PEMBRO-RT study demonstrate when an ICI-mediated Abscopal effect is most likely to occur in patients with stage IV NSCLC. <a href="/rweichselbaum/">Ralph Weichselbaum</a> <a href="/SeanPitroda/">Sean Pitroda, M.D.</a> <a href="/dramycummings/">Amy L. Cummings, MD PhD</a> doi.org/10.1038/s43018…
TMC Radiation Oncology (@radonctmc) 's Twitter Profile Photo

𝑡𝒖𝒂𝒏𝒄𝒆𝒔 𝒐𝒇 𝑷𝒓𝒐𝒕𝒐𝒏 π‘©π’†π’‚π’Ž π‘»π’‰π’†π’“π’‚π’‘π’š: π‘­π’“π’π’Ž π‘ͺπ’π’Žπ’Žπ’Šπ’”π’”π’Šπ’π’π’Šπ’π’ˆ 𝒕𝒐 π‘ͺπ’π’Šπ’π’Šπ’„π’” XXII Tata Memorial Hospital Annual Radiotherapy Practicum & 1st TMC - IBA Proton Therapy Practicum πŸ—“ 12-13 September 2025 πŸ“ACTREC-TMC πŸ”— Register tinyurl.com/46pmefum

𝑡𝒖𝒂𝒏𝒄𝒆𝒔 𝒐𝒇 𝑷𝒓𝒐𝒕𝒐𝒏 π‘©π’†π’‚π’Ž π‘»π’‰π’†π’“π’‚π’‘π’š: π‘­π’“π’π’Ž π‘ͺπ’π’Žπ’Žπ’Šπ’”π’”π’Šπ’π’π’Šπ’π’ˆ 𝒕𝒐 π‘ͺπ’π’Šπ’π’Šπ’„π’”

XXII <a href="/TataMemorial/">Tata Memorial Hospital</a> Annual Radiotherapy Practicum
&amp;
1st TMC - IBA Proton Therapy Practicum

πŸ—“ 12-13 September 2025
πŸ“<a href="/ACTREC_TMC/">ACTREC-TMC</a>

πŸ”— Register tinyurl.com/46pmefum
David Palma, MD, PhD (@drdavidpalma) 's Twitter Profile Photo

Important re-irradiation lesson for #radonc residents: when you look at your DVH in EQD2 (like in MIM), the "V20" that you need to look at will change. Here's a DVH from a 60/30 plan shown as physical dose vs. EQD2. The DVH looks much better below 60 Gy & a bit worse above it.

Important re-irradiation lesson for #radonc residents: when you look at your DVH in EQD2 (like in MIM), the "V20" that you need to look at will change. 

Here's a DVH from a 60/30 plan shown as physical dose vs. EQD2. The DVH looks much better below 60 Gy &amp; a bit worse above it.
Tata Memorial Hospital (@tatamemorial) 's Twitter Profile Photo

Glad to share that our staff published 52 papers in July, spanning cancer prevention & treatment, managing complications, health policy & quality improvement, contributing to generating high quality Indian evidence for treating our patients. ACTREC-TMC Tata Memorial Centre, Varanasi (MPMMCC & HBCH) Cancer Research Institute - ACTREC